Methods of providing therapeutic effects using cyclosporin components
Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
1 . A method of treating an eye of a human or animal comprising:
administering to an eye of a human or animal a composition in the form of an emulsion comprising water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition, the weight ratio of the cyclosporin component to the hydrophobic component is less than 0.08.
2 . The method of claim 1 wherein the administering step is effective in treating a condition selected from the group consisting of dry eye syndrome, phacoanaphylactic endophthalmitis, uveitis, vernal conjunctivitis, atopic keratoconjunctivitis and corneal graft rejection.
3 . The method of claim 1 wherein the administering step is effective in treating dry eye syndrome.
4 . The method of claim 1 wherein the blood of the human or animal has substantially no detectable concentration of the cyclosporin component.
5 . The method of claim 1 wherein the blood of the human or animal has substantially no detectable concentration of the cyclosporin component as measured using a validated liquid chromatography/mass spectrometry-mass spectrometry analytical method.
6 . The method of claim 1 wherein the blood of the human or animal has a concentration of the cyclosporin component of 0.1 ng/ml or less.
7 . The method of claim 1 wherein the cyclosporin component comprises a material selected from cyclosporin A, derivatives of cyclosporin A and mixtures thereof.
8 . The method of claim 1 wherein the cyclosporin component comprises cyclosporin A.
9 . The method of claim 1 wherein the cyclosporin component is solubilized in the hydrophobic component present in the composition.
10 . The method of claim 1 wherein the hydrophobic component is present in the composition in an amount greater than 0.625% by weight of the composition.
11 . The method of claim 1 wherein the hydrophobic component comprises an oily material.
12 . The method of claim 1 wherein the hydrophobic component comprises an ingredient selected from the group consisting of vegetable oils, animal oils, mineral oils, synthetic oils and mixtures thereof.
13 . The method of claim 1 wherein the hydrophobic component comprises castor oil.
14 . The method of claim 1 wherein the administering step comprises topically administering the composition to the eye of the human.
15 . The method of claim 1 wherein the composition comprises an effective amount of an emulsifier component.
16 . The method of claim 1 wherein the composition comprises an effective amount of a tonicity component.
17 . The method of claim 1 wherein the composition comprises an effective amount of an organic tonicity component.
18 . The method of claim 1 wherein the composition comprises a polyelectrolyte component in an amount effective in stabilizing the composition.
19 . The method of claim 1 wherein the composition has a pH in the range of about 7.0 to about 8.0.
20 . The method of claim 1 wherein the composition has a pH in the range of about 7.2 to about 7.6.
21 . A composition for treating an eye of a human or animal comprising an emulsion comprising water, a hydrophobic component, and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight, the weight ratio of the cyclosporin component to the hydrophobic component being less than 0.08.
22 . The composition of claim 21 having a make-up so that when the composition is administered to an eye of a human in an effective amount in treating dry eye syndrome, the blood of the human has substantially no detectable concentration of the cyclosporin component.
23 . The composition of claim 21 wherein the cyclosporin component comprises a material selected from cyclosporin A, derivatives of cyclosporin A and mixtures thereof.
24 . The composition of claim 21 wherein the cyclosporin component comprises cyclosporin A.
25 . The composition of claim 21 in the form of an emulsion.
26 . The composition of claim 21 wherein the hydrophobic component is present in an amount greater than 0.625% by weight of the composition.
27 . The composition of claim 21 wherein the hydrophobic component is an oily material.
28 . The composition of claim 21 wherein the hydrophobic component comprises an ingredient selected from the group consisting of vegetable oils, animal oils, mineral oils, synthetic oils, and mixtures thereof.
29 . The composition of claim 21 wherein the hydrophobic component comprises castor oil.
30 . The composition of claim 21 wherein the administering step comprises topically administering the composition to the eye of the human.
31 . The composition of claim 21 wherein the composition comprises an effective amount of an emulsifier component.
32 . The composition of claim 21 wherein the composition comprises an effective amount of a tonicity component.
33 . The composition of claim 21 wherein the composition comprises an effective amount of an organic tonicity component.
34 . The composition of claim 21 wherein the composition comprises a polyelectrolytic component in an amount effective in stabilizing the composition.
35 . The composition of claim 21 wherein the composition includes water and has a pH in the range of about 7.0 to about 8.0.
36 . The composition of claim 21 wherein the composition includes water and has a pH in the range of about 7.2 to about 7.6.